GlobeNewswire Inc | Oct 6, 2020 05:17PM EDT

October 06, 2020

NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced thatJohn Houston, Ph.D., President and Chief Executive Officer, will present a keynote plenary session at the 3rd Annual Targeted Protein Degradation Summit being held virtually October 14-15, 2020. The presentation will reflect on Arvinas advances in its PROTAC platform and introduce new pipeline programs.

Presentation Details:

Title: The Promise of PROTAC Protein Degraders: Whats Next for Arvinas Pipeline & PlatformDate: Wednesday, October 14, 2020Time: 11:30 a.m. ET

AboutArvinasArvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the bodys own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

Contacts for Arvinas

InvestorsWill OConnor, Stern Investor Relationsir@arvinas.com

MediaKirsten Owens, Arvinas Communicationskirsten.owens@arvinas.com